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Summary With the association of 5-fluorouracil (5-FU) and alpha-interferon (IFN), objective responses as
high as 26-63% have been reported in untreated patients with advanced colorectal cancer. However, grade 3-
4 toxicity has also been reported. We have conducted a prospective phase II randomised study comparing 5-FU
to 5-FU+IFN, to investigate whether the addition of IFN to a weekly 5-FU regimen devoid of significant
toxicity used at our institutions could improve the effectiveness of 5-FU while maintaining acceptable toxicity.
Patients with histologically proven advanced colorectal carcinoma were randomised to receive 5-FU
500 mg m-2 intravenous (i.v.) bolus on days 1-5 followed by 5-FU 500 mg m-2 i.v. bolus weekly from
day 15, with or without IFN alpha-2a intramuscularly (i.m.) 1.5 mU daily on days 6-12 and 3 mU i.m. daily
thereafter. The treatment was administered on an outpatient basis. Response was evaluated every 3 months,
and treatment continued until progression or after two consecutive judgements of stable disease. Response rate
was the main end point of the study. Of 141 patients eligible, 72 were randomised to 5-FU alone (arm A) and
69 to 5-FU+IFN (arm B). Responses were 9/72 (12.5%) in arm A and 6/69 (8.7%) in arm B; complete
responses were three in arm A and two in arm B. Progression-free survival (median 4 months) and survival
(median 12 months) were identical in the two arms. Toxicity was almost absent in arm A and moderate in arm
B, represented mainly by haematological toxicity (usually leucopenia). In conclusion, overall survival was good
in both arms of treatment and toxicity was moderate. While the response rate with 5-FU alone was in accord
with the literature data, response to 5-FU+IFN was lower than expected. At least at this dosage and schedule,
the association of 5-FU and IFN is no better than 5-FU alone and is of no clinical interest.
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There is presently no standard treatment for advanced
colorectal cancer. Treatment with 5-FU induces response
rates of around 15-20%, while attempts at modulating 5-FU
activity, or using aggressive combination chemotherapy,
might result in an increased response rate but barely affect
survival.
With the association of 5-FU and alpha-interferon (IFN)
objective responses in 13/17 untreated patients were initially
reported (Wadler et al., 1989). Response rates ranging from
26% to 63% have subsequently been obtained in other trials
(Kemeny et al., 1990; Wadler et al., 1991; Padzur et al.,
1993); however, severe toxicity (grade 3-4) with the
combination was also reported, including diarrhoea, neurol-
gical complications and toxic deaths. Futhermore, the impact
of this combination on survival is not clear.
In October 1990 we started a prospective phase II
randomised study comparing 5-FU with 5-FU +IFN in
advanced, untreated colorectal carcinoma, with the aim of
evaluating the effect on response and survival of the addition
of IFN to a weekly 5-FU regimen of limited toxicity
commonly administered on an outpatient basis at our
institutions.
Patients and methods
Patients with histologically proven advanced colorectal
cancer, evaluable disease, age <75 years, performance status
ECOG 0-1, life expectancy of 3 months or more, and no
previous chemotherapy, were randomised to receive 5-
FU mg m-2 i.v. bolus (15 min infusion in saline) on days
1-5 and then weekly from day 15 (arm A); or 5-FU +IFN
alpha-2a i.m. 6 mU day-' (arm B); IFN was started at day 6
and given at half dose for the first week. The initially planned
IFN dose of 6 mU day-' was abandoned after 4 months of
study, as a result of both systemic and haematological
toxicity registered in the first patients, and a dose of 3 mU
day- was used in the following patients. Response was
evaluated every 3 months and treatment continued until
progression or after two consecutive judgments of stable
disease. Staging and follow-up clinical assessment included
haematochemistry, tumour markers, abdominal computed
tomography (CT) or ultrasound, chest radiograph, plus other
tests depending on the site of involvement. Oral informed
consent was a prerequisite for study entry.
Evaluation of response and toxicity was by standard
criteria (Miller et al., 1981). The following dose adjustments
were applied: 5-FU was delayed by 1 week and IFN was
given at half dose for WBC between 2 000 and 3 000 or
platelets between 75 000 and 100 000; for lower values, 1
week delay for both drugs was required. Paracetamol 500-
1000 mg orally was used in association with IFN, usually
limited to the first weeks of treatment.
The estimated sample size was of 82 patients per arm,
sufficient to show a difference of response rate from 15%
(expected from 5-FU alone) to 35% (5-FU + IFN) at a
significance level of 0.05 with a power of 80%. Statistical
evaluation was accomplished by intention-to-treat analysis.
The characteristics of patients in arm A and B were
compared by the Wilcoxon test (age and time from
diagnosis) and by the chi-square test (sex, site of primary,
performance status). Overall response rates were compared
by the chi-square test. Survival curves were estimated by the
Kaplan-Meier method (Kaplan and Meier, 1958) and
compared by the log-rank test (Peto and Peto, 1972).
Results
A total of 142 patients were randomised from October 1990
to December 1993. At that time, response rate and its
confidence limits in arm B were shown to be inferior to those
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in arm A and judged to be of no clinical interest and accrual
was stopped. Of the 142 patients enrolled, one patient was
found to be ineligible since further diagnostic work-up
following randomisation showed focal liver lesions, pre-
viously interpreted as metastases, to be benign lesions. This
patient is still alive and with no evidence ofdisease (NED) 30
months after randomisation. All other patients are included
in the analysis and evaluated by intention-to-treat. Of 141
eligible patients, 88 were male and 53 female, with a median
age of 62 years. Primary site was colon in 104 cases and
rectum in 37 cases.
Seventy-two patients were randomised to arm A and 69
patients were randomised to arm B; the characteristics of the
two groups were comparable (Table I), with no statistically
significant difference found (not shown). Approximately 25%
of patients had significant cancer-related symptoms (19/72 in
arm A, 18/69 in arm B), while the vast majority of patients
were asymptomatic.
Protocol deviations were: two patients randomised to arm
B were treated with aggressive platinum-based chemotherapy,
since the origin of their tumour from the intestinal tract was
not accepted as conclusive by the responsible physicians; one
of these patients had a partial response (PR) followed by
progression (P) at 26 months and is still alive 40 months from
the start of treatment. One patient per arm over the age of 75
and in good general condition was randomised and
evaluated, as well as two patients per arm with performance
status ECOG 2 (Karnofsky 60).
Responses were 9/72 (12.5%) in arm A and 6/69 (8.7%) in
arm B; 95% confidence limits showed wide overlap between
the two groups (Table II). The difference in response rates
was 3.8% in favour of 5-FU alone; the 95% confidence
interval for this difference was -8.4% to 16.0%. An
advantage in favour of the combination of 5-FU+ IFN
higher than 8.4% can therefore be confidently excluded at the
95% level based on these data.
Complete responses (CR) were three in arm A and two in
arm B. Progression-free survival (median 4 months) and
survival (median 12 months) were identical in the two arms
(Figures 1 and 2). Duration of response was 5-15 months in
arm A; in arm B, four patients survived without progression
for more than 20 months. Two of them were CR patients
with disease involving liver and distant nodes, and liver and
Table I Characteristics of the patients
Arm A Arm B
(S-FU) (5-FU+IFN)
Number of patients 72 69
Age (years)
Median 61.5 62.9
Range 34-78 33-77
Sex (M/F) 47/25 41/28
Site of primary (colon/rectum) 54/18 50/19
Time from diagnosis to
treatment (months)
Median 2.6 2.7
Range 0-129 0-96
Performance status (ECOG)
0 53 51
1 17 16
2 2 2
Number of sites involved
1 57 55
2 9 10
3 6 4
Maximum extension of disease
Abdominopelvic 16 10
Hepatic 39 40
Extraabdominal 17 19
bone respectively; both of them are still alive with NED at 41
and 36 months; another patient with liver involvement had
stable disease (SD), still stable at 23 months; the fourth was
one of the patients treated with an aggressive platinum-
containing regimen, since an ovarian origin of the tumour
could not be completely ruled out; this patient had a partial
response and progressed after 26 months.
Nine patients in arm A and 5 patients in arm B were not
evaluable for response (and respectively nine and seven for
toxicity). Reasons for non-evaluability were: refusal to
continue treatment beyond 1 month (seven patients in arm
A, one patient in arm B), treatment received different from
treatment planned (two patients in arm A, three patients in
arm B), early cessation of treatment for cardiac ischaemia
(one patient in arm B).
Table II Response to treatment
Arm A Arm B
(S-FU) (S-FU+IFN)
Number of patients 72 69
Patients evaluable for response 63 64
Complete responses (CR) 3 2
Partial responses (PR) 6 4
Overall response 9/72 6/69
percentage 12.5 89.7
(95% confidence limits of the (4.9-20.1) (2.0-15.3)
percentage)
Median time to progression (months) 4 4
Median survival (months) 12 12
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Figure 1 Progression-free survival curves for the two arms,
calculated from date of randomisation to first progression.
Kaplan-Meier estimates ( ), 5-FU (n =72); (- - - -), 5-
FU+IFN (n=69).
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Figure 2 Survival curves for the two arms, calculated from date
of randomisation to death. Kaplan-Meier estimates. ( ), 5-
FU (n=75); (- - - -), 5-FU+IFN (n=69).Response by site of involvement is depicted in Table LII. The
most frequently involved site was the liver, where responses
were observed in approximately 10% of patients; response
rate was higher for nodal involvement.
Toxicity was almost absent in arm A and moderate in arm
B, represented mainly by haematological toxicity, usually
leucopenia (Table IV). In the initial part of the study, with
IFN at 6 mU day-', systemic (fever, flu-like syndrome) and
haematological toxicities were more severe and did not allow
patients to receive the planned treatment in seven of eight
instances; the eighth patient refused to double the dose from
3 mU to 6 mU. Grade 1-2 gastrointestinal toxicity was
common and was mainly represented by transient diarrhoea,
while mucositis, nausea and vomiting were infrequently
observed; mild toxicity related to IFN (fever, flu-like
syndrome) was common in arm B, usually limited to the
first 1 -2 weeks of treatment and controlled by oral
paracetamol. The dose of 5-FU received was approximately
10% lower in arm B than in arm A (Table IV); IFN was
given at approximately 80% of the planned dose.
Since response to 5-FU+IFN was low (with upper 95%
confidence limit at 15%) and very unlikely to be influenced
by completion of accrual (82 patients per arm planned), the
overall result was judged of no interest, and the trial was
stopped.
Discussion
The treatment of advanced colorectal cancer traditionally
relies on drugs and combinations devoid of signifcant
toxicity. Attemps have been made recently towards more
aggressive chemotherapy regimens. These have in general
resulted in improved response rates; effects on survival are
less clear. Most of the combinations employed are 5-FU-
based regimens, in which the added drugs are biochemical
modulators of the 5-FU effects (Peters and van Groningen
1992).
One of these recently introduced 5-FU modulators is a-
interferon. After the experimental demonstration that IFN is
able to increase the anti-tumour activity of 5-FU (Pfeffer and
Tamm, 1984; Elias and Sandoval, 1989; Chu et al., 1990;
Danhauser et al., 1993; Houghton et al., 1993), several
Table III Response after 3 months, by site involvement
Arm A (5-FU) Arm B (5-FU+aIFN)
No. of No. No. of No.
patients evaluable OR patients evaluable OR
Primary 11 7 1 12 11 0
tumour
Liver 51 41 4 52 47 5
Lung 14 14 1 11 10 0
Peritoneal 6 6 2 5 5 1
Skin 3 1 0 4 4 0
Bone 2 2 1 5 3 1
Distant 5 3 1 7 5 3
nodes
OR, odds ratio.
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studies were performed in order to evaluate the role of the
association of the two drugs in a clinical setting. Although
the exciting results initially reported by Wadler et al. (1989)
were not completely confirmed by others, a response rate of
30-40% was commonly observed; however, severe associated
toxicity (mucositis, diarrhoea, leucopenia, neurological
impairment and toxic deaths) was also reported (Kemeny et
al., 1990; Wadler et al., 1991; Pazdur et al., 1993), while the
effect on survival is entirely unclear. In addition, optimal
doses and schedules have yet to be identified.
The aim of the present study was to evaluate the
contribution of IFN to the clinical activity of a weekly
administration of 5-FU, devoid of relevant toxicity and given
entirely on an outpatient basis, commonly employed at our
institutions as palliative treatment of advanced colorectal
cancer. The dosage of 5-FU was in the range of clinical
effectiveness yet with low toxicity (500 mg m-2 weekly);
schemes of equivalent dose intensity have been reported
effective and are currently used in clinical trials (Lokich et al.,
1989; Leichman et al., 1995).
The dosage of IFN was the maximum allowed in our
patients. A dose of 6 mU day-' (42 mU per week) was
planned, but was shown in the first patients treated in our
study not to be feasible; most of the patients received
3 mU day-1.
The results obtained in our study showed a response rate
to the combination similar to that obtained with 5-FU alone,
with identical time to progression and overall survival.
Several theorectical reasons might explain this failure of
IFN to improve the effectiveness of 5-FU. One of these could
be the use of a lower dose of IFN than that employed in the
original scheme by Wadler et al. (1989). However, the few
phase II studies employing low-dose IFN showed low toxicity
and a response rate close to 30% (Botto et al., 1991; Hansen
et al., 1993; Meehan et al., 1993).
Another possible cause could be our choice ofgiving 5-FU
by bolus injections (even in the loading course). However, on
the basis of literature data (John et al., 1993; Pazdur et al.,
1993; Leichman et al., 1995), it is unlikely that such a
difference in activity could be explained by this change of
schedule only.
Contrasting results have been reported in randomised
trials comparing 5-FU to 5-FU +IFN, with one study in
which responses were higher with the combination (26.8% vs
10.1% with 5-FU alone) and also survival analysis showed a
moderate but significant advantage in favour of the
combination (Dreyfus et al., 1995). In the majority of
studies the 5-FU/IFN combination failed to show any
therapeutic improvement compared with 5-FU alone, while
the incidence and severity of toxicity was significantly higher
(York et al., 1993; Corfu-A Study Group, 1995; Hill et al.,
1995). Increase in incidence of toxic effects, without increase
in response rates, was also recorded when IFN was added to
a 5-FU/leucovorin combination in randomised trials
(Seymour et al., 1994; Kohne et al., 1995).
Furthermore, in our study, despite the use of a
combination of 5-FU and IFN of moderate toxicity, a dose
reduction was often required for both drugs because of
toxicity, and the attempts to use IFN at a higher dosage soon
had to be abandoned.
Table IV Dose intensity and leucopenia during the first 6 months of treatment
Arm A (5-FU) Arm B (5-FU+IFN)
No. of Leucopenia No. of Leucopenia
patients %FU Gr 1 2 3 patients %FU %IFN Gr 1 2 3
Month 1 63 96 12 6 3 62 94 84 10 14 4
Month 2 58 98 5 1 1 58 91 80 17 10 0
Month 3 52 99 6 1 0 55 90 81 17 8 0
Month 4 34 97 5 3 0 33 89 80 13 5 0
Month 5 30 98 8 0 0 26 90 80 9 1 0
Month 6 26 98 5 1 0 22 93 78 7 3 0
Gr, grade.xFU with or wiRtt FN i cokoretl cancer
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In conclusion. the addition of IFN to 5-FU at doses of the
two drugs devoid of significant toxic effects did not result in
improved efficacy with respect to 5-FU alone. As was recently
stressed (Kemeny. 1995). the heterogeneity of the patients
with advanced colorectal cancer might account for the
vanability of response rates and survival in this disease and
the difficulty of obtaining univocal results in clinical trials.
Since advanced colorectal carcinoma is a condition in which
survival times seem to be independent from any presently
available medical treatment, the attempts at improving
response rates, by testing more toxic and expensive
combinations should be limited to expenrmental clinical
setting and avoided in routine clinical practice.
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